- Company
- New diabetes treatment guidelines released
- by Kim, Jin-Gu May 15, 2023 05:41am
- The status of GLP-1 analogues and SGLT-2 inhibitors has risen further in Korea’s new diabetes treatment guidelines. In the revised guidelines, when considering options to use in combination with injection therapy, GLP-1 analogues were recommended over basal insulin, and SGLT-2 inhibitors were recommended first for diabetic patients with hear
- InterView
- ‘Even a 0.2 vision is a miracle to some’
- by Eo, Yun-Ho May 15, 2023 05:41am
- The reason for the slow development of new drugs in a specific disease can usually be attributed to one of the following two reasons. Low disease awareness or difficulty in developing the drug itself. The one-shot gene therapy Novatis’s ‘Luxturna (voretigene neparvovec)’ is a drug that overcame both barriers. Luxturna, which is a treat
- Company
- MSD Korea begins voluntary retirement
- by Jung, Sae-Im May 15, 2023 05:40am
- MSD Korea, which announced a reduction in manpower due to the abolition of the Januvia division, has begun a full-fledged reduction in personnel by disclosing the conditions for ERP. The labor union of MSD Korea warned of a tough response, saying, "We cannot accept the company's attempt to reduce manpower." On the 12th, MSD Korea announced t
- Company
- Advate leading hemophilia treatment
- by Nho, Byung Chul May 12, 2023 05:45am
- In the field of hemophilia non-antibody and antibody treatment, Takeda Korea Pharmaceutical and JW Pharmaceutical are gaining attention as they are strengthening their positions. Korea Takeda Pharmaceutical's 'Advate/Adynovate', and JW Pharmaceutical's Hemlibra's sales last year were 26.2 billion won and 7.6 billion won, respectively, ran
- Company
- SK Biopharm’s cenobamate secures KRW 700 billion
- by Chon, Seung-Hyun May 12, 2023 05:45am
- Cumulative sales of SK Biopharmaceutical’s epilepsy treatment cenobamate exceeded KRW 300 billion in the US. It had continued to show growth every quarter ever since its release. Combined with the upfront payment and milestone payments cenobamate has earned more than KRW 700 billion over the past 4 years. According to SK Biopharm on the 11th
- Policy
- Youkyung Oh was appointed as the first chairman of APFRAS
- by Lee, Hye-Kyung May 12, 2023 05:44am
- On the 10th and 11th, the Ministry of Food and Drug Safety (Minister Oh Yookyung) held the 1st Asia-Pacific Food Regulatory Authority Heads Consultative Meeting (APFRAS 2023), where 7 countries came together to harmonize global food regulations in the Asia-Pacific region and strengthen cooperation. said to have collected. APFRAS (Asia-Pacif
- Policy
- HIRA plans to report on the re-evaluation
- by Lee, Tak-Sun May 12, 2023 05:44am
- It is known that The HIRA will come up with a plan to improve the re-evaluation of drug benefits and report it to the Health Insurance Policy Review Committee of the Ministry of Health and Welfare, which will be held this month. This improvement plan is based on the 'rationalization plan for re-evaluation of drug benefit adequacy', which end
- Company
- SU's strengths maximized through combined use with SGLT-2is
- by Kim, Jin-Gu May 12, 2023 05:44am
- New opportunities have emerged for the use of the diabetes treatment sulfonylurea (SU). It is claimed that its combined use with SGLT-2 inhibitor drugs can offset the existing disadvantages such as hypoglycemia and weight gain, while fully utilizing the strong blood sugar lowering effect of SU drugs. Professor Jin Hwa Kim of the Depart
- Policy
- Triple-negative breast cancer tx Trodelbi approved in Korea
- by Lee, Hye-Kyung May 11, 2023 05:50am
- Meditip's Trodelbi (Sacituzumabgovitecan), an orphan drug triple-negative breast cancer treatment, has received domestic product approval. The Ministry of Food and Drug Safety (Minister Oh Yoo-kyung) announced on the 9th that it had approved the approval of Trodelbi to be used in breast cancer patients who lack estrogen receptor (ER), progestero
- Policy
- ‘Pay more policy attention to advanced heart failures'
- by Hwang, byoung-woo May 11, 2023 05:49am
- [Interview with Medical Societies] Soo-Yong Lee, Administrative Secretary of the Insurance Committee at KSF Asks authorities to increase benefits for patients at high risk of health failure who have fewer treatment alternatives According to the ‘2020 Heart Failure Fact Sheet’ that was released by the Korean Society of Heart Failure (KSHF),
